triazoles has been researched along with End Stage Liver Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Huang, J; Li, L; Yang, Q | 1 |
| Boyd, SD; McLaughlin, M; Morse, CG; Pau, AK; Penzak, SR | 1 |
2 other study(ies) available for triazoles and End Stage Liver Disease
| Article | Year |
|---|---|
Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study.
Topics: Adult; Antifungal Agents; Cross Infection; End Stage Liver Disease; Female; Humans; Invasive Pulmonary Aspergillosis; Itraconazole; Male; Middle Aged; Pyrimidines; Risk Factors; Survival Rate; Triazoles; Voriconazole | 2013 |
Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
Topics: Adult; Cyclohexanes; Disease Management; End Stage Liver Disease; Fatal Outcome; HIV Infections; Humans; Male; Maraviroc; Metabolic Clearance Rate; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Triazoles | 2012 |